Description
Sogroya (generic: somapacitan-beco) is a prescription injection solution made by Novo Nordisk for subcutaneous use. It contains somapacitan at 3.3 mg/mL strength and was approved under BLA761156, with marketing starting in May 2023. This information was generated using AI and is provided for informational and research purposes only.
Resources
| Name | Format | Description | Link |
|---|---|---|---|
| Somapacitan-beco | HTML | Access the FDA dataset for Somapacitan-beco — ANDA 761156 submitted by Mylan Institutional LLC | Open resource |